

Convenient Synthesis of Some Novel 4-Benzyl-1(2H)-Phthalazinone Derivatives of expected anticancer activity

Samir M. El Rayes¹, Ibrahim A. I. Ali¹, Hamdy A. Soliman¹, Sara M. Emam²

¹*Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt*

²*Micro-analytical and Toxicology Research Unit & Central Lab, Faculty of Science, Suez Canal University, Ismailia, Egypt*

Abstract

Series of new synthesized biologically active phthalazinone derivatives were obtained. Starting from the amino acid methyl esters of 4-benzyl-1(2H)-phthalazinone **2a,b** which were synthesized from the aceto hydrazide of 4-benzyl-1(2H)-phthalazinone **1** *via* azide coupling method. The hydrazides **3a,b** were prepared from hydrazinolysis of corresponding esters **2a,b**. *N*-substituted-2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-methyl-acetamide **4a-f** and the dipeptides methyl {2-[2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetylamino]-acetylamino}-alkanoates **6a-c** were obtained by the reaction of corresponding hydrazide **3a** with amines and amino acid esters respectively *via* azide coupling method.

Similarly; *N*- substituted -3-[2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetyl amino] propionamide **5a-f** and the dipeptides methyl{3-[2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetylamino]-propionylamino} alkanoates **7a-c** were obtained by the reaction of corresponding hydrazide **3b** with amines and amino acid esters respectively *via* azide coupling method

Keywords: Chemoselective, phthalazinone, azide, amines, amino acids, dipeptide

Introduction

Cancer is one of the most difficult diseases to treat and it is a major disease responsible for deaths worldwide, it can be considered as one of the foremost health problems¹. Therefore, anticancer drugs research is never ending to obtain lower toxicity and more selectivity products towards tumor cells. It is an urgent need to give much attention to update and modify drug leads from the point of view of medicinal chemistry and drug design to fulfill more potent and effective therapies. Recently, Our research group focused their efforts on searching for new anticancer drugs^{2,3}.

phthalazinone derivatives have found application in clinical medicine due to their pronounced antihypertensive properties⁴, cardiotoxic^{5,6}, anticonvulsant^{7,8}, antidiabetic^{9,10}, antithrombotic¹¹, antimicrobial^{12,13}, antipyretic, analgesic, antitumor¹⁴⁻¹⁷ and cytotoxic¹⁸.

A series of 4-substituted-2H-phthalazin-1-ones have been investigated as potent orally bioavailable PARP (poly (adenosine diphosphate-ribose) polymerases) inhibitor¹⁹⁻²⁶ Olaparib **I**, MRU-868 **II** and KU0058958 **III** are the most interesting PARP inhibitors based on the 4-substituted-2H-phthalazin-1-one scaffold and compound **IV** inhibits aurora-A kinase based upon a 4-(pyrazole-3-ylamino)phenyl-2H-phthalazin-1-one scaffold and has in vitro cytotoxic activity against HCT116 colon cell line²⁷, these commercial phthalazinone derivatives are shown in figure 1.




Figure 1: Some phthalazinone anticancer drugs

We will present new compound designs from N-substituted phthalazin-1-one derivatives based on the 4-benzylphthalazin-1-one scaffold in an attempt to obtain a potent anticancer agent.

Discussion


Our research group reported early that²⁸⁻³¹, how we can control on chemoselective alkylation in both amides and thioamides. As extension of these studies, we achieve N-alkylation of 4-Benzyl-2H-phthalazin-1-one to the corresponding methyl-4-Benzyl-1-oxo-1H-phthalazin-2-yl-acetate to the corresponding (4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetic acid hydrazide (**1**) which used as a precursor for the preparation of our targeted newly phthalazinone molecules.

The alkylation reaction proceeds selectively on N atom not at O atom or even in competition reaction at both atoms. We can explain that depending on their behavior towards electrophiles according to reaction control points as basicity and nucleophilicity of both N and O atoms. The product was methyl-4-Benzyl-1-oxo-1H-phthalazin-2-yl-acetate prove that the N atom in present system is stronger nucleophile more than Oxygen i.e this reaction is new evidence for basis of chemoselective reactivity of heterocyclic amides towards electrophiles scheme1.

The chemoselectivity alkylation proved that occur on the N- atom not the O- isomer so this reaction is N- regioselective and this can be dedicated by the structure characterization using ^1H and ^{13}C - NMR spectroscopy.


General procedure for 4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetic acid hydrazide (**1**)

The phthalazine aceto hydrazide **1** was prepared by four steps procedure as outlined in scheme 1 starting from the fusion of phthalic anhydride with phenyl acetic acid in the presence of fused sodium acetate in sand bath from 230 to 240°C yielding 3-benzal phthalide³², which reacted with hydrazine hydrate in boiling ethanol to give the benzyl phthalazinone derivative³³. The benzyl phthalazinone derivative was refluxed with ethyl chloro acetate in the presence of anhydrous K_2CO_3 in boiling DMF/ acetone (1:1) led to the oxophthalazinyl acetate compound that was converted to the desired acetohydrazide **1** by reaction with hydrazine hydrate in boiling ethanol³⁴.



Scheme (1): Synthesis of hydrazide **1**

According to the azide coupling method³⁵, the aceto hydrazide derivative **1** was stirred with sodium nitrite and hydrochloric acid mixture at -5°C forming azide molecule that in ethyl acetate solution react with amino acid ester hydrochloride in the presence of tri ethyl amine afforded the N-substituted amino acid methyl esters of 4-benzyl-1(2*H*)-phthalazinone **2a,b** (Gly and β -Ala) in good yield in scheme 2.




Scheme 2: Preparation of amino acid ester compounds **2a,b** and their corresponding hydrazides **3a,b**







The glycine methyl ester of 4-benzyl-1(2*H*)-phthalazinone **2a** has the ^1H - NMR spectrum of characteristic signals at 3.64 , 4.2 , 4 and 4.9 ppm for O-CH₃, N-CH₂ , CH₂.CO and CH₂-Ph groups respectively and the ^{13}C - NMR spectrum has signals at 159.78, 167.72 169.99 for 3C=O groups 54.8 , 52.27 , 41.29 and 38.91 ppm, O-CH₃, N-CH₂ , CH₂.CO and CH₂-Ph groups respectively .

N-substituted amino acid methyl esters of 4-benzyl-1(2*H*)-phthalazinone **2a,b** were considered key intermediates for our chemical structure modification of phthalazinone nucleus. The esters **2a,b** underwent hydrazinolysis *via* reflux with hydrazine hydrate in ethanol forming corresponding hydrazides **3a,b**.

Under azide coupling condition, the 2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-N-hydrazinocarbonylmethyl-acetamide **3a** was treated with a mixture of sodium nitrite and HCl solution to give its corresponding azide solution which further treatment with different amines like n-benzyl, n-propyl, n-butyl, cyclohexyl, tetradecyl and allyl amines gave corresponding *N*-substituted -2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-methyl-acetamides **4a-f**.


Similarly, starting from the 2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-N-(2-hydrazinocarbonyl-ethyl)-acetamide **3b** under same azide coupling condition, *N*-substituted -3-[2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetyl amino]propionamide **5a-f** were obtained as shown in scheme 3.



4	n	R	5	n	R
a	0		a	1	
b	0	CH₃-CH₂-CH₂	b	1	CH₃-CH₂-CH₂
c	0	CH₃-CH₂-CH₂- CH₂	c	1	CH₃-CH₂-CH₂- CH₂
d	0		d	1	
e	0	CH₃- (CH₂)₁₄	e	1	CH₃- (CH₂)₁₄
f	0		f	1	

Scheme 3: Synthesis of *N*-substituted-2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-amides **4,5a-f**

The azide form of 1-oxo-1H-phthalazin-2-yl)-N-hydrazino carbonyl methyl-acetamide **3a** was coupled with different amino acid methyl esters of glycine, β -alanine and valine affording (dipeptides) methyl-2-[2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetylamino]-acetylamino-alkanoates in reasonable yield **6a-c**. Under the same condition, methyl-3-[2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-acetylamino]-propionylamino-alkanoates **7a-c** were synthesized from corresponding hydrazide 2-(4-Benzyl-1-oxo-1H-phthalazin-2-yl)-N-(2-hydrazinocarbonyl-ethyl)-acetamide **3b** as shown in scheme 4.



6	n	R	7	n	R
a	0	H	a	1	H
b	0	H-CH₂	b	1	H-CH₂
c	0	CH₃-CH- CH₃	c	1	CH₃-CH- CH₃

Scheme 4: Synthesis of dipeptide derivatives **6,7a-c**.

References

- 1- C. Avendano, J.C. Menendez, Medicinal Chemistry of Anticancer Drugs, First ed., Elsevier, **2008**, p. 1 (Chapter 1).
- 2- El-Rayes, S., Gomaa, M.S., Abouelmagd, A., Fathalla, W., Ali, I.A.I. Synthesis and antiproliferative assay of triazolyl-2,2-dimethyl-3-phenylpropanoates as potential HDAC inhibitors *RSC Advances* **2019**, 9(24), 13896.
- 3- S. M. El Rayes, A. Abo Elmagd, Gomaa M. S., Ibrahim A. I. Ali, Walid Fathalla, Faheem Hyder Pottoo, F. A. Khan Convenient synthesis and antiproliferative activity of methyl 2-[3-(3-phenylquinoxalin-2-ylsulfanyl)propanamido] alkanoates and N-Alkyl 3-((3-phenylquinoxalin-2-yl)sulfanyl) propanamides accepted in *ACS Omega* **2019** DOI 10.1021/acsomega.9b02320

- 4- Demirayak S, Karaburun AC, Beis R. Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. *Eur. J. Med. Chem.*, **2004**, 39, 1089–1095.
- 5- Munín J, Santana L, Uriarte E, Borges F, Quezada E. A comparative synthesis of 6-benzyl 2,3-dihydroimidazo[2,1-a]phthalazine and 2H-7-benzyl-3,4-dihydropyrimido[2,1-a]phthalazine. *Tetrahedron Lett.*, **2015**, 56, 828–830.
- 6- Nomoto Y, Obase H, Takai TH, Teranishi M, Nakamura J, Kubo K. Studies on cardiotonic agents. II. Synthesis of novel phthalazine and 1,2,3-benzotriazine derivatives. *Chem. Pharm. Bull.* **1990**, 38, 2179–2183.
- 7- Grasso S, De Sarro G, De Sarro A, Micale N, Zappalà M, Puja G, Baraldi M, De Micheli C. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones. *J. Med. Chem.*, **2000**, 43, 2851–2859.
- 8- Sivakumar R, Kishore Guanasam S, Ramachandran S, Leonard JT. Pharmacological evaluation of some new 1-substituted-4-hydroxyphthalazines. *Eur. J. Med. Chem.*, **2002**, 37, 793–801.
- 9- Madhavan GR, Chakrabarti R, Kumar SKB, Misra P, Mamidi RNVS, Balraju V, Kasiram K, Babu RK, Suresh J, Lohray BB, Lohray VB, Iqbal J, Rajagopalan R. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents. *Eur. J. Med. Chem.*, **2001**, 36, 627–637.
- 10- Lenz EM, Wilson LD, Wright B, Partridge EA, Rodgers CT, Haycock PR, Lindon JC, Nicholson JK. A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. *J. Pharm. Biomed. Anal.*, **2002**, 28, 31–43.

- 11- Johansen M, Rehse K, Pertz H, Stasch JP, Bischoff E. New antithrombotic 1 phthalazinamines with serotonin antagonistic properties. *Arch. Pharm.*, **2003**, 336, 591–597.
- 12- Pramanik A. Synthesis of biologically important phthalazinones, 2,3-benzoxazin-1-ones and isoindolinones from ninhydrin and their antimicrobial activity. *Tetrahedron Lett.*, **2013**, 54, 3137–3143.
- 13- Shetgiri NP, Nayak BK. Synthesis and antimicrobial activities of oxadiazoles, phthalazines and indolinones. *Indian J. Chem.*, **2005**, 44B, 1267–1272.
- 14- Cockcroft X, Dillon KJ, Dixon L, Drzewiecki J, Kerrigan F, Loh VM Jr, Martin NMB, Menear KA, Smith GCM. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADPribose) polymerase. *Bioorg. Med. Chem. Lett.*, **2006**, 16, 1040–1044.
- 15- Loh VM Jr, Cockcroft X, Dillon KJ, Dixon L, Drzewiecki J, Eversley PJ, Gomez S, Hoare J, Kerrigan F, Matthews IT, Menear KA, Martin NM, Newton RF, Paul J, Smith GC, Vile J, Whittle AJ. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADPribose)polymerase. *Bioorg. Med. Chem. Lett.*, **2005**, 15, 2235–2238.
- 16- Eldehna WM, Ibrahim HS, Abdel-Aziz HA, Farrag NN, Youssef MM. Design, synthesis and in vitro antitumor activity of novel Nsubstituted- 4-phenyl/benzylphthalazin-1-ones. *Eur. J. Med. Chem.*, **2015**, 89, 549–560.
- 17- Haider N, Kabicher T, Käferböck J, Plenk A. Synthesis and in-vitro antitumor activity of 1-[3-(indol-1-yl)prop-1-yn-1-yl]phthalazines and related compounds. *Molecules*, **2007**, 12, 1900–1909.
- 18- Kim JS, Lee HJ, Suh ME, Choo HY, Lee SK, Park HJ, Kim C, Park SW, Lee CO. Synthesis and cytotoxicity of 1-substituted 2-methyl- 1H-

- imidazo[4,5-g]phthalazine-4,9-dione derivatives. *Bioorg. Med. Chem.*, **2004**, 12, 3683–3686.
- 19- I.H. Hall, E.S. Hall, O.T. Wong, *Anti Cancer Drugs* 3 (1992) 55e62.
- 20- I.H. Hall, D.W. Covington, J.R. Wheaton, R.A. Izydore, X. Zhou, *Pharmazie* **2001**, 56, 168-174.
- 21- V.M. Loh, X.-l. Cockcroft, K.J. Dillon, L. Dixon, J. Drzewiecki, P.J. Eversley, S. Gomez, J. Hoare, F. Kerrigan, I.T.W. Matthews, K.A. Menear, N.M.B. Martin, R.F. Newton, J. Paul, G.C.M. Smith, J. Vilec, A.J. Whittlec, *Bioorg. Med. Chem. Lett.* **2005**, 15, 2235-2238.
- 22- X.L. Cockcroft, K.J. Dillon, L. Dixon, J. Drzewiecki, F. Kerrigan, V.M. Loh, N.M.B. Martin, K.A. Menear, G.C.M. Smith, *Bioorg. Med. Chem. Lett.* **2006**, 16, 1040-1044.
- 23- K.A. Menear, C. Adcock, R. Boulter, X.-l. Cockcroft, L. Copsey, A. Cranston, K.J. Dillon, J. Drzewiecki, S. Garman, S. Gomez, H. Javaid, F. Kerrigan, C. Knights, A. Lau, V.M. Loh, I.T.W. Matthews, S. Moore, M.J. O'Connor, G.C.M. Smith, N.M.B. Martin, *J. Med. Chem.* **2008**, 51, 6581-6591.
- 24- Prime M.E., Courtney S.M., Brookfield F.A, Marston R.W., Walker V., Warne J., Boyd A.E., Kairies N.A., von der Saal W., Limberg A., Georges G., Engh R.A., Goller B., Rueger P., Rueth M. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of aurora-A kinase. *J. Med. Chem.*, **2011**, 54, 312–319 ().
- 25- *Organic Syntheses*, Coll., **1943**, 2, 61; **1933**, 13, 10
- 26- El-Wahab AHFA, Mohamed HM, El-Agrody AM, El-Nassag MA, Bedair AH. Synthesis and biological screening of 4-benzyl-2Hphthalazine derivatives. *Pharmaceuticals*, **2011**, 4, 1158–1170

- 27- Marzouk.M.I; Shaker.S.A; Abdel Hafiz.A.A& *et al*: Design and Synthesis of New Phthalazinone Derivatives Containing Benzyl Moiety with Anticipated Antitumor Activity, *Biol. Pharm. Bull.*: **2016**, 39, 239–251.
- 28- Ibrahim. A. I. Ali, Walid Fathalla, S. M. El Rayes Convenient syntheses of methyl 2-[2-(3-acetyl-4-methyl-2-oxo-1,2-dihydroquinolin-1-yl)acetamido] alkanoates and their O-regioisomers *ARKIVOC* **2008** (xiii) 179-188
- 29- S. M. El Rayes Convenient synthesis of some methyl-N-[2-(3-oxo-6-p-tolyl-2,3,4,5-tetrahydropyridazin-2-yl)-acetylamino]amino acid esters *ARKIVOC* **2008** (xvi) 243-254
- 30- S. M. El Rayes Convenient Synthesis and Antimicrobial Activity of Some Novel Amino Acid Coupled Triazoles *Molecules* **2010**, 15, 6759-6772; doi:10.3390/molecules15106759
- 31- Walid Fathalla, S. M. El Rayes, Ibrahim A. I. Ali Convenient synthesis of 1-substituted-4-methyl-5-oxo [1,2,4]triazolo[4,3-a]quinazolines *ARKIVOC* **2007** (xvi) 173-186
- 32- Hofmann, K.; Thompson, T. A.; Yajima, H.; Schwarts, E. T.; Enouye, H. J. *Am. Chem. Soc.* 1960, 82, 3715.
- 33- Ali. I.A. , Fathallah. W. & Elrayes.S.M.; 2008: Convenient syntheses of methyl 2-[2-(3-acetyl-4-methyl-2-oxo-1,2-dihydroquinolin-1-yl)acetamido] alkanoates and their O-regioisomers, *ARKIVOC* (xiii) 179-188.
- 34- Eldehna W.M. , Ibrahim H.S. , Abdel-Aziz H.A. & et al ;: Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones , *European Journal of Medicinal Chemistry* **2015**, (89) , 549-560.
- 35-** Elrayes.S.M, ; Ali. I.A. & Fathallah. W;; Convenient Synthesis of Some Novel Pyridazinone Bearing Triazole Moieties, *Journal of Heterocyclic Chemistry* : **2019**, 56, 51, DOI: 10.1002/3369.